Amendola Communications has been selected as the public relations agency of record for Sentrian, the Remote Patient Intelligence company aspiring to eliminate all preventable hospitalisation.

Sentrian, recognised by the START programme as one of the world's highest-potential and most disruptive technology companies, aspires to eliminate all preventable hospitalisation by leveraging the revolution in remote biosensors and machine learning to detect patient deterioration early, before it becomes acute.

The award-winning Amendola team helped to formally launch Sentrian at Singularity University's Exponential Medicine Conference in San Diego, Nov. 10, delivering significant positive media coverage of the launch in Healthcare IT News, Hospitals & Health Networks, MedCity News, and several other leading healthcare IT trade publications.

Sentrian chose to partner with Amendola Communications based on the agency's deep experience in healthcare and HIT public relations and marketing. The agency will provide a full range of PR services including strategic counsel, media and analyst relations, content development, and management and support for speaker and award opportunities.

"We were attracted to Amendola Communications by the creative strengths and media savvy of their veteran team, whose collective experience representing startups and public companies is unmatched in the healthcare IT space," says Dean Sawyer, Co-Founder and CEO of Sentrian. "In the short time we've worked together they have proven the value of their deep relationships with key media and demonstrated again and again their ability to work collaboratively in the high-energy do-or-die mode of a technology startup."   

In addition to Sawyer, who is a former senior executive of Allscripts and Physicians Interactive, Sentrian's leadership team includes chief medical scientist Martin Kohn, MD, MS, FACEP, previously the Chief Medical Scientist for Care Delivery Systems in IBM Research.

Sentrian's platform is currently being tested by large health insurance plans in controlled studies involving thousands of patients.  The company expects to announce the results of those studies in 2015.